Cited 0 times in
ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin-angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 안철민 | - |
dc.date.accessioned | 2022-12-22T02:36:16Z | - |
dc.date.available | 2022-12-22T02:36:16Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191646 | - |
dc.description.abstract | Background: Limited data are available comparing the combined effects of statins and renin-angiotensin system inhibitor (RASI) between patients with ST-segment elevation myocardial infarction (STEMI) and those with non-STEMI (NSTEMI). We compared the effects of statins combined with RASI in STEMI and NSTEMI patients after stent implantation during a long-term follow-up period. Methods: A total of 21,890 acute myocardial infarction (AMI) patients who underwent successful stent implantation and who received statins with RASI were enrolled. They were separated into the STEMI group (n = 12,490) and the NSTEMI group (n = 9400). The major clinical endpoint was the occurrence of major adverse cardiac events (MACEs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization. Results: Two propensity score-matched (PSM) groups (5891 pairs, n = 11782, C-statistic = 0.821) were generated. Even though the cumulative incidences of MACE, re-MI, total repeat revascularization were similar between the two groups, the cumulative incidences of all-cause death (hazard ratio [HR] 1.407; 95% confidence interval [CI] 1.106-1.790; p = 0.005) and cardiac death (HR 1.311; 95% CI 1.983-1.749; p = 0.046) were significantly higher in the NSTEMI group. Conclusions: In this study, statin with RASI combination therapy was more beneficial to the STEMI patients than to the NSTEMI patients in reducing all-cause death and cardiac death. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Via Medica | - |
dc.relation.isPartOf | CARDIOLOGY JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antihypertensive Agents / therapeutic use | - |
dc.subject.MESH | Death | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use | - |
dc.subject.MESH | Myocardial Infarction* / diagnosis | - |
dc.subject.MESH | Myocardial Infarction* / drug therapy | - |
dc.subject.MESH | Myocardial Infarction* / etiology | - |
dc.subject.MESH | Non-ST Elevated Myocardial Infarction* / diagnosis | - |
dc.subject.MESH | Non-ST Elevated Myocardial Infarction* / drug therapy | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / adverse effects | - |
dc.subject.MESH | Registries | - |
dc.subject.MESH | Renin-Angiotensin System | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | ST Elevation Myocardial Infarction* / drug therapy | - |
dc.subject.MESH | ST Elevation Myocardial Infarction* / therapy | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin-angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yong Hoon Kim | - |
dc.contributor.googleauthor | Ae-Young Her | - |
dc.contributor.googleauthor | Myung Ho Jeong | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Seunghwan Kim | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.identifier.doi | 10.5603/CJ.a2021.0007 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A05648 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J03125 | - |
dc.identifier.eissn | 1897-5593 | - |
dc.identifier.pmid | 33634844 | - |
dc.subject.keyword | ST-segment elevation myocardial infarction | - |
dc.subject.keyword | non-ST-segment elevation myocardial infarction | - |
dc.subject.keyword | renin–angiotensin system | - |
dc.subject.keyword | statin | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 647 | - |
dc.citation.endPage | 659 | - |
dc.identifier.bibliographicCitation | CARDIOLOGY JOURNAL, Vol.29(4) : 647-659, 2022-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.